- United States
- /
- Software
- /
- NasdaqGS:CDNS
Cadence Design Systems (NasdaqGS:CDNS) Price Rises 14% Over Last Quarter
Reviewed by Simply Wall St
In May 2025, Cadence Design Systems (NasdaqGS:CDNS) launched the Millennium M2000 Supercomputer, delivering enhanced AI-accelerated simulations, alongside the Tensilica NeuroEdge 130 AI Co-Processor, optimizing neural processing. Despite these advancements, broader market trends like investor optimism over reduced tariffs between the U.S. and China may have provided a conducive environment for Cadence's stock price to rise 14% during the last quarter, aligning with the broader technology market movement. Meanwhile, Q1 2025 earnings demonstrated strong financial results, potentially reinforcing investor confidence amidst this upward trajectory.
Cadence Design Systems' recent advancements in AI-accelerated simulations and neural processing, through the Millennium M2000 Supercomputer and Tensilica NeuroEdge 130 AI Co-Processor, can potentially strengthen its AI-driven design and verification tools portfolio. These innovations may boost revenue, meeting increasing demand for their AI-enabled offerings and supporting future earnings growth. Analysts expect revenue to rise, driven by strong IP business performance and expanding partnerships with major industry players, though geopolitical risks pose challenges.
Over the past five years, Cadence experienced a total shareholder return of 211.71%, reflecting robust long-term growth. However, when comparing performance over the past year, Cadence underperformed the US Software industry, which returned 22.8%. This short-term underperformance contrasts with the company's five-year success and may influence investor perceptions.
Despite the recent positive news, Cadence's current share price of US$305.78 is relatively close to the consensus analyst price target of US$319.32, representing a modest 4.2% upside. This suggests that while recent developments are promising, the market may already be pricing in these advancements. Investors are encouraged to weigh these factors alongside the analysts' forecasts and company valuation when considering their stance on Cadence's long-term potential.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The New Payments ETF Is Live on NASDAQ:
Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.
Explore how this launch could reshape portfolios
Sponsored ContentNew: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:CDNS
Cadence Design Systems
Provides software, hardware, and other services worldwide.
Excellent balance sheet with moderate growth potential.
Similar Companies
Market Insights
Weekly Picks
THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

The Quiet Giant That Became AI’s Power Grid
Recently Updated Narratives
Deep Value Multi Bagger Opportunity

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
